obesity glp1

Obesity and weight loss, led by GLP-1 drugs: the drugs, and the products and services built around them.

Theme · 7 companies · 1 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ADRX ADARx Pharmaceuticals, Inc.

    In development“Our adipose-targeted obesity program, ADX-077, is designed to reduce body weight and fat while preserving lean mass.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • AMGN Amgen

    In development“It is being investigated for the treatment of chronic weight management, cardiovascular disease, heart failure, obstructive sleep apnea and Type 2 diabetes.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • LLY Eli Lilly and Company

    Sells it 56%, $36.5B a year“For the treatment of adults with obesity or overweight with at least one weight-related comorbid condition in combination with a reduced-calorie diet and increased physical activity; and for the treatment of moderate to severe obstructive sleep apnea in adults with obesity in combination with a reduced-calorie diet and increased physical activity (relevant indications marketed under Mounjaro in various markets outside the U.S.).”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • OURA Oura Inc.

    Sells it“This is a dedicated companion experience designed for members taking GLP-1 medications.”

    Latest S-1/Aamended IPO prospectusPositiveLegal / investigationProceeds to insiders or debt ·

    Smart rings and health subscriptions; offering mainly benefits selling holders, while company proceeds largely cover equity-award taxes

  • PFE Pfizer

    In development

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • VOGX Vogenx, Inc.

    In development“There is a need for treatment options to maintain the weight loss once patients discontinue GLP-1 therapies.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernRestatementAccounting issue ·

    Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

  • VRHI Veri MedTech Holdings, Inc.

    In development“Weight Loss Treatments: GLP-1s, Peptides, and Metabolism Boosters”

    Latest S-1/Aamended IPO prospectusNegativeBankruptcy / going concernAccounting issueControlled company ·

    Connects patients with physicians for medical-cannabis certifications; FY2025 revenue fell 34.9% Y/Y as state restrictions hit consultations

Feedback